Despite regular co-vaccination of two different strains of live infectious bronchitis vaccine viruses, little is known about possible mutations in these viruses following vaccination. As an alternative to chicks, this study used an in vitro infection model to identify single-nucleotide polymorphisms (SNPs) within the part-S1 gene of two live infectious bronchitis virus vaccine strains (793B and Massachusetts) following single or dual inoculation onto tracheal organ cultures. Results indicate that viral titres reduced over the duration of the study; conversely, the amount of detected infectious bronchitis virus genome increased. Results demonstrate a greater number of nonsynonymous SNPs in both vaccine strains when they are co-inoculated, compared with the single inoculations. The influence of the increased SNP and hydrophobic properties of the translated proteins on the vaccine viruses' virulence is unknown.
Infectious bronchitis virus (IBV) is a globally important poultry pathogen (Dolz et al., 2008; Jones, 2010) . Since the first description of IBV in the 1930s (Schalk & Hawn, 1931) , there have been a number of genotypes reported worldwide that are known to infect chicken, such as Massachusetts (Mass), Connecticut, Arkansas, 793B, It-02, QX, Q1 and Dutch strains (Jackwood, 2012) . Live IBV vaccines, often two different serotypes, are co-administered to young chicks for protection against most virulent viruses (Awad et al., 2016; Chhabra et al., 2015; De Wit et al., 2015) .
Single-nucleotide polymorphisms (SNPs) are genetic mutations that can have important downstream effects on the translated protein for IBV (Zhao et al., 2014) . Introduction of SNPs may alter IBV field strains, creating strain variants or even new genotypes (Ducatez et al., 2009) . There is limited information regarding genetic variations arising within IBV vaccine strains following co-vaccination in young chicks.
Tracheal organ cultures (TOCs) have previously been used for examining viruses, including IBV, within an in vitro environment (Raj & Jones, 1996; Wang et al., 1997; Winter et al., 2008) . Such studies have allowed for the comparison of strain virulence, analysis of infection mechanisms and virus neutralization. As an alternative to the use of chicks, we attempted to study the interactions between two common live IBV vaccine strains (Mass and 793B). In addition to any genetic changes detected by reverse transcriptase PCR (RT-PCR) and sequencing, the tracheal ciliary viability and IBV growth (viable and non-viable) were also assessed every 24 h. The use of this in vitro infection model would assist in reducing the use of animals in experimental studies.
Two commercially available live IBV vaccines, Ma5 (!10 3.5 egg infective dose (EID) 50 ) and 4/91 (!10 3.6 EID 50 ), were dissolved in sterile distilled water and used for either single or dual infection.
TOCs were prepared from 20-day-old embryonated specific-pathogen-free chicken eggs (Cook et al., 1976) . Briefly, tracheas were removed under sterile conditions, cut into 0.6-mm-thick rings using a McIlwain tissue chopper (Mickle Laboratory Engineering) and individually transferred into sterile tubes containing 600 µl of TOC medium (minimum essential medium, sodium bicarbonate and 0.4 % penicillin/streptomycin). Tubes were incubated at 37 C in a rotating incubator.
One hundred and sixty TOC tubes were divided into four groups of 40. At day 0, all tubes had 100 % cilia activity. Commercial vaccines were reconstituted according to the manufacturer's instructions Chhabra et al., 2015) , and each tube was inoculated with 100 µl (equivalent to per chick dosage) of vaccine according to the following: group A, Mass; group B, 793B; group C, Mass +793B; group D, sterile distilled water (unvaccinated control). At the point of inoculation, and then for every 24 h up to 7 days post-inoculation (p.i.), the cilia activity for each TOC tube was recorded: 0, 75 to 100 % beating; 1, 50 to 75 % beating; 2, 25 to 50 % beating; 3, 0 to 25 % beating; 4, no beating (complete ciliostasis) (Cook et al., 1989) . Each day, tubes with a score of 4 were removed, and additional tubes were randomly selected to make a total of five for each group per sampling day. Using five per sampling day allowed for an average SNP reading per day, rather than relying on a single sample. If more than five showed complete ciliostasis, all applicable tubes were removed on that sampling day. These TOCs were stored at À20 C for RNA extraction.
From each of the removed TOCs, 100 µl of medium was taken for RNA extraction using the RNeasy kit (Qiagen) according to the manufacturer's instructions. Extracted RNA was subjected to RT-PCR to detect a 393 bp partial-S1 sequence in the hypervariable region of the S1 gene (Awad et al., 2014; Cavanagh et al., 1999; Ganapathy et al., 2015; Worthington et al., 2008) . In previous genotyping studies, this region was targeted due to the increased genetic variation possibilities. For these reasons, our analysis concentrated on the S1 hypervariable region.
Following RT-PCR, positive samples (and the original inoculated vaccine strains) were purified and submitted for commercial bi-directional sequencing (Source Bioscience) and analysed in MEGA6 (Tamura et al., 2013) . BLAST analysis was carried out to confirm the genotype of the recovered strain. Sequences were aligned to the inoculated vaccine strains, with both SNPs and translated amino acid variations identified. SNP data are expressed per 100 bp, with amino acid changes expressed per 100 aa. Viral growth kinetics were measured for each group by pooling supernatant from each removed tube according to sampling day (1-4 days p.i.). Tenfold serial dilutions were inoculated onto TOCs for virus titration (Reed & Muench, 1938) , and RNA was extracted for a quantitative RT-PCR (qRT-PCR) assay using the RNeasy kit (Qiagen) (Jones et al., 2011) . Obtained C t values from qRT-PCR were converted to log relative equivalent units (REU) of RNA as previously described by Chhabra et al. (2015) and Löndt et al. (2013) .
The majority (87.5 %) of the TOCs in the control group remained viable (>90 % ciliary beating) until the end of the study (7 days p.i.). For the infected TOCs, at 3 days postinfection, six showed complete ciliostasis (group A, 1; group B, 1; group C, 4), and by day 4, the remaining TOCs in groups A and B had no cilia activity (Table 1) .
Using polynomial regression, the cilia activity results allowed us to identify the point at which only 50 % of the TOC tubes still had viable cilia activity (Raj & Jones, 1996) . Results showed that the combined vaccine group Supernatant removed on each sampling day was pooled, and growth kinetics were measured over the study period. Virus titration in TOCs demonstrated a titre reduction in all groups over the 4 days. By 4 days p.i., only the 793B (group B) and combined group (group C) showed a positive IBV titre (Fig. 2a) . Additionally, quantification by qRT-PCR showed that both the 793B and combined groups demonstrated a higher log REU concentration at 4 days p.i. compared with the Mass group (group A) (0.38 and 0.39 log REU compared with 0.34, respectively) (Fig. 2b ). on the host-agent interactions following single or dual vaccination of these vaccine viruses. This is of interest, in particular in the trachea since it is one of the main virus replication sites for IBV. In this study, we used chick TOCs to investigate the molecular changes in the part-S1 gene of these vaccine viruses given either singly or dually.
In this experiment, for the combined group, the two commercial strains were mixed without adjusting for their respective titres, as they are normally administered for field vaccination of chicks. The experiment was designed to mimic field practices, with the main objective of evaluating the molecular changes in the S1 gene when the live vaccine viruses are coadministered. However, following inoculation, we saw a rapid decrease in cilia viability within the first 2 days in all virus inoculated groups. Comparing the number of days taken for 50 % of the TOCs to become non-viable (Raj & Jones, 1996) , the dual inoculation of two IBV genotypes had a greater detrimental effect on cilia beating than the two singly inoculated groups. This is particularly noticeable when compared to the Mass vaccine, 1.37 days, and when compared to 0.99 days in the dual inoculation group.
In the combined group, only two recovered sequences were identified as Mass. The remaining 31 were 793B, suggesting that when the vaccine viruses are co-inoculated in TOCs, the 793B genotype may have the ability to replicate at a faster rate than Mass. It is known that simultaneous IBV and avian metapneumovirus (aMPV) vaccination can impair the effective replication of aMPV live vaccines in chicks (Cook et al., 2001) . Working with aMPV and Newcastle disease virus interaction, Ganapathy et al. (2007) reported a delayed detection of aMPV by RT-PCR. We witnessed a similar situation for the two IBV vaccine serotypes in this study.
Growth kinetic data demonstrated a decrease over the study period in viable viral titre (as measured by TOC titration). A similar finding has been reported previously, with the titres of several IB strains decreasing in TOCs after 24 h inoculation (Hodgson et al., 2004) . Conversely, qRT-PCR results showed an increase in total viral amount by 4 days p.i. The number of IBV genome copies increased over time, whereas the viral titre decreased, suggesting that the replication of the virus decreases with reduction in the available epithelial cells. Conversely, the increase in the log REU over the study duration shows the ability of the qRT-PCR to measure both viable and non-viable IBV genomes (Roh et al., 2014) . By 3 and 4 days p. i., the log REU in all infected groups increased markedly reflecting replication of the vaccine viruses prior to the sampling points. Still, it would have been of interest to examine the viral titre at 1 h p.i. to confirm replication.
Based on RT-PCR and growth kinetic data, it appears that when Mass and 793B are given simultaneously with similar viral titres (Mass, 10 4.75 TCID 50 ; 793B, 10 4.4 TCID 50 ), the 793B became the dominant virus to recover throughout the study. In this group, the Mass vaccine virus was only detected twice compared with the daily detections in the single Mass group. It would be of interest to study the impact of co-administration of these vaccines in young chicks.
In comparing the single inoculation groups, given the lower SNP counts, the individual 793B vaccine appeared to have a greater stability when compared to the individual Mass vaccine. These results are in concurrence with previous in vivo work, which demonstrated that the majority of nucleotide variations in 793B were synonymous (Cavanagh et al., 2005) . However, in the presence of Mass (Group C), there was a marked increase in 793B SNPs per 100 bp (particularly at 4 days p.i., 0.55 per 100 bp in the dual compared with 0.03 in the single vaccinations), with the majority now causing a change in the amino acid composition. This suggests that competition for replication may have impacted on the genetic variability in the sequenced 793B vaccine strain. Similarly, the Mass vaccine also showed an increase in nucleotide variations following combined vaccination (Domingo & Holland, 1997) .
Despite marked increase in detected amino acid changes per sample in group C (3.85 and 10.5 times higher for Mass and 793B, respectively) compared with the individual groups, there was no consistent change among the analysed sequences (Fig. 1) . In previous work, Cavanagh et al., 1988 described how a single amino acid change could alter the neutralizing antibodies. Any potential effects on the in vivo virulence of the recovered strains are unknown and were not investigated in this study. While recombination events can occur between coronaviruses (Lai & Cavanagh, 1997) , and particularly among IBV strains (Abolnik, 2015) , no such activity was witnessed during this study where only the part-S1 gene was analysed.
In this study, we attempted to assess the genetic changes in an in vitro infection model, which allows free replication of the viruses in the absence of adaptive host immunity, repeat exposures or other factors related to host or environment. Establishing a reliable in vitro system would allow for further studies of many other live IBV vaccines and reduce use of animals in experiments. Findings from this work need to be evaluated in vivo, as host immunity and environmental factors could potentially alter the outcomes. In addition, instead of part-S1, extending the molecular analysis to the full S1 gene or the whole genome may provide valuable information on the host-IBV interactions.
